5.49

0.90% -0.05

After Hours: 5.51 0.02 +0.36%

Taysha Gene Therapies Inc (TSHA)

Overview News Price History Option Chain Financials Discussions Forecast

Taysha Gene Therapies Inc stock is traded at $5.49, with a volume of 1.65M. It is down -0.90% in the last 24 hours and down -18.30% over the past month. Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

Previous Close:

$5.54

Open:

$5.54

24h Volume:

1.65M

Relative Volume:

0.61

Market Cap:

$1.58B

Revenue:

$9.77M

Net Income/Loss:

$-109.00M

P/E Ratio:

-15.23

EPS:

-0.3604

Net Cash Flow:

$-93.83M

1W Performance:

-7.89%

1M Performance:

-18.30%

6M Performance:

+31.03%

1Y Performance:

+92.63%

1-Day Range:

$5.42

$5.6725

1-Week Range:

$5.17

$6.04

52-Week Range:

$2.25

$7.30

Taysha Gene Therapies Inc Stock (TSHA) Company Profile

Name

Taysha Gene Therapies Inc

Sector

Healthcare (1108)

Industry

Biotechnology (618)

Phone

(214) 612-0000

Address

3000 PEGASUS PARK DRIVE, DALLAS

Employee

Twitter

Next Earnings Date

2026-05-06

Latest SEC Filings

TSHA's Discussions on Twitter

Compare TSHA vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TSHA Taysha Gene Therapies Inc	5.49	1.59B	9.77M	-109.00M	-93.83M	-0.3604
VRTX Vertex Pharmaceuticals Inc	434.52	110.03B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	638.88	67.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	806.46	50.76B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	297.45	40.12B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	151.56	32.68B	742.00K	-1.37B	-1.07B	-7.0731

Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-21-25	Initiated	Raymond James	Strong Buy
Jul-11-25	Initiated	BofA Securities	Buy
Jun-27-24	Initiated	BMO Capital Markets	Outperform
Apr-09-24	Initiated	Piper Sandler	Overweight
Feb-01-23	Downgrade	Jefferies	Buy → Hold
Jan-27-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-09-22	Downgrade	Goldman	Buy → Neutral
Mar-09-22	Initiated	Robert W. Baird	Outperform
Mar-01-22	Initiated	Wells Fargo	Overweight
Feb-18-22	Initiated	SMBC Nikko	Outperform
Dec-16-21	Initiated	Guggenheim	Buy
Jul-16-21	Initiated	Needham	Buy
Jun-24-21	Initiated	Truist	Buy
Jun-15-21	Initiated	BTIG Research	Buy
Jun-09-21	Initiated	Wedbush	Outperform
Jun-08-21	Initiated	JMP Securities	Mkt Outperform
May-19-21	Initiated	Cantor Fitzgerald	Overweight
May-11-21	Resumed	Jefferies	Buy
Feb-24-21	Initiated	William Blair	Outperform
Jan-05-21	Initiated	Oppenheimer	Outperform
Oct-19-20	Initiated	Chardan Capital Markets	Buy
Oct-19-20	Initiated	Goldman	Buy
Oct-19-20	Initiated	Jefferies	Buy
Oct-19-20	Initiated	Morgan Stanley	Overweight

View All

Taysha Gene Therapies Inc Stock (TSHA) Latest News

03:27 AM

Taysha Gene Therapies stock hits all-time high at 5.49 USD - Investing.com Australia

03:27 AM

May 23, 2026

B of A Securities Initiates Coverage of Taysha Gene Therapies (TSHA) with Buy Recommendation - MSN

May 23, 2026

May 22, 2026

BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $10 - Moomoo

May 22, 2026

May 19, 2026

Taysha Gene Therapies’ SWOT analysis: stock faces pivotal trial test By Investing.com - Investing.com Canada

May 19, 2026

Taysha Gene Therapies’ SWOT analysis: stock faces pivotal trial test - Investing.com

May 19, 2026

May 17, 2026

Taysha soars on FDA breakthrough therapy status for lead asset - MSN

May 17, 2026

May 15, 2026

Vestal Point and Ryan Wilder hold 6.3% of Taysha Gene Therapies (TSHA) - Stock Titan

May 15, 2026

RTW Investments and R. Wong report 20.7M shares in Taysha (NASDAQ: TSHA) - Stock Titan

May 15, 2026

May 14, 2026

Possible Bearish Signals With Taysha Gene Therapies Insiders Disposing Stock - Moomoo

May 14, 2026

Taysha Gene Therapies (TSHA) Reports Financial Results for Q1 2026 - Insider Monkey

May 14, 2026

TSHA-102 construct design study advances Rett syndrome research at ASGCT 2026 - Traders Union

May 14, 2026

May 12, 2026

Taysha Gene Therapies, Inc. engages Rettsyndrome community at Patient First event - Traders Union

May 12, 2026

May 11, 2026

Canaccord Keeps Buy Rating on Taysha (TSHA) After Q1 Highlights - Insider Monkey

May 11, 2026

May 10, 2026

Taysha Gene Therapies Ramps Up Ahead of TSHA-102 BLA - TipRanks

May 10, 2026

May 09, 2026

Assessing Taysha Gene Therapies (TSHA) Valuation After Strong Momentum And Recent Volatility - Yahoo Finance

May 09, 2026

Taysha (TSHA) Q1 2026 Earnings Transcript - AOL.com

May 09, 2026

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2026 Earnings Call Transcript - Insider Monkey

May 09, 2026

May 08, 2026